Quality of life in irritable bowel syndrome: Measurement techniques and relevance of current knowledge

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 3, Issue 1, 2003, Pages 75-88

  Simrén, Magnus ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Disease specific instruments; Functional gastrointestinal disorders; Genetic instruments; Health related quality of life; Irritable bowel syndrome; Psychometric properties; Reliability; Responsiveness; Validation

Indexed keywords

ACETORPHAN; ALOSETRON; DESIPRAMINE; ENKEPHALINASE INHIBITOR; FEDOTOZINE; LEUPRORELIN; OPIATE AGONIST; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; BEHAVIOR THERAPY; CLINICAL FEATURE; COGNITIVE THERAPY; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; HEALTH STATUS; HUMAN; HYPNOSIS; IRRITABLE COLON; MEASUREMENT; MENTAL HEALTH; NAUSEA; OUTCOMES RESEARCH; POPULATION RESEARCH; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; SIDE EFFECT; VALIDATION PROCESS; WELLBEING;

EID: 0037321193     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.3.1.75     Document Type: Review

References (103)

1. Constitution of the World Health Organization. Handbook of basic documents. 5th ed. World Health Organization, Palais des Nations, Geneva, Switzerland (1952).
2. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann. Intern. Med. 118(8), 622-629 (1993).
3. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 45(Suppl. 2), II43-47 (1999).
4. Agreus L, Svärdsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109(3), 671-680 (1995).
5. Drossman DA, Li Z, Andruzzi E et al. US householder survey of functional gastrointestinal disorders. Prevalence, sociodemography and health impact. Dig. Dis. Sci. 38(9), 1569-1580 (1993).
6. Longstreth GF, Wolde-Tsadik G. Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics and clinical correlates. Dig. Dis. Sci. 38(9), 1581-1589 (1993).
7. Talley NJ, Boyce P, Jones M. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population. Gut 42(5), 690-695 (1998).
8. Heaton KW, O'Donnell LJ, Braddon FE, Mountford RA, Hughes AO, Cripps PJ. Symptoms of irritable bowel syndrome in a British urban community: consulters and nonconsulters. Gastroenterology 102(6), 1962-1967 (1992).
9. Talley NJ, Boyce PM, Jones M. Predictors of healthcare seeking for irritable bowel syndrome: a population based study. Gut 41(3), 394-398 (1997).
10. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics and referral. Gut 46(1), 78-82 (2000).
11. Harvey RF, Salih SY, Read AE. Organic and functional disorders in 2000 gastroenterology out-patients. Lancet 1(8325), 632-634 (1983).
12. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther. 16(6), 1171-1185 (2002).
13. Lea R, Whorwell PJ. Quality of life in irritable bowel syndrome. PharmacoEconomics 19(6), 643-653 (2001).
14. Luscombe FA. Health-related quality of life and associated psychosocial factors in irritable bowel syndrome: a review. Qual. Life Res. 9(2), 161-176 (2000).
15. Veldhuyzen van Zanten SJ, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 45(Suppl. 2), 1169-1177 (1999).
16. Drossman DA, Patrick DL, Mitchell CM, Zagami EA, Appelbaum MI. Health-related quality of life in inflammatory bowel disease. Functional status and patient worries and concerns. Dig. Dis Sci. 34(9), 1379-1386 (1989).
17. Borgaonkar MR, Irvine EJ. Quality of life measurement in gastrointestinal and liver disorders. Gut 47(3), 444-454 (2000).
18. Eisen GM, Locke GR 3rd, Provenzale D. Health-related quality of life: a primer for gastroenterologists. Am. J. Gastroenterol. 94(8), 2017-2021 (1999).
19. Sullivan M. Quality of life assessment in medicine. Concepts, definitions, purposes and basic tools. Nord. J. Psychiatry 46, 79-83 (1992).
20. Ware JE Jr. Standards for validating health measures: definition and content. J. Chronic Dis. 40(6), 473-480 (1987).
21. Patrick DL, Erickson P. Assessing health-related quality of life for clinical decision-making. In: Quality of life Assessment - Key Issues in the 1990s. Walker SR, Rosser RM (Ed.). Kluwer Academic Publishers, Lancaster, UK, 11-63 (1993).
22. Creed F, Ratcliffe J, Fernandez L et al. Health-related quality of life and healthcare costs in severe, refractory irritable bowel syndrome. Ann. Intern. Med. 134(9 Pt 2), 860-868 (2001).
23. Gralnek IM, Hays RD, Killbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 119(3), 654-660 (2000).
24. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life. Aliment Pharmacol. Ther. 11(3), 553-559 (1997).
25. Hahn BA, Yan S, Strassels S. Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom Digestion 60(1), 77-81 (1999).
26. Lee OY, Fitzgerald LZ, Naliboff B et al. Impact of advertisement and clinic populations in symptoms and perception of irritable bowel syndrome. Aliment Pharmacol. Ther. 13(12), 1631-1638 (1999).
27. O'Keefe EA, Talley M, Zinsmeister AR, Jacobsen SJ. Bowel disorders impair functional status and quality of life in the elderly: a population-based study. J. Gerontol. A. Biol. Sci. Med. Sci. 50(4), M184-189 (1995).
28. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig. Dis. Sci. 43(2), 400-411 (1998).
29. Schmulson M, Lee OY, Chang L, Naliboff B, Mayer EA. Symptom differences in moderate to severe IBS patients based on predominant bowel habit. Am. J. Gastroenterol. 94(10), 2929-2935 (1999).
30. Whitehead WE, Burnett CK, Cook EW 3rd, Taub E. Impact of irritable bowel syndrome on quality of life. Dig. Dis. Sci. 41(11), 2248-2253 (1996).
31. Akehurst RL, Brazier JE, Mathers N et al. Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. PharmacoEconomics 20(7), 455-462 (2002).
32. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 262(7), 907-913 (1989).
33. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 30(6), 473-483 (1992).
34. McHorney CA, Ware JE Jr, Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. Med. Care 30(5 Suppl), MS253-265 (1992).
35. McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med. Care 31(3), 247-263. (1993).
36. Koloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am. J. Gastroenterol 95(1), 67-71 (2000).
37. Simrén M, Månsson A, Langkilde AM et al. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 63(2), 108-115 (2001).
38. Fass R, Fullerton S, Naliboff B, Hirsh T, Mayer EA. Sexual dysfunction in patients with irritable bowel syndrome and non-ulcer dyspepsia. Digestion 59(1), 79-85 (1998).
39. Elsenbruch S, Harnish MJ, Orr WC. Subjective and objective sleep quality in irritable bowel syndrome. Am. J. Gastroenterol. 94(9), 2447-2452 (1999).
40. Drossman DA, Whitehead WE, Toner BB et al. What determines severity among patients with painful functional bowel disorders? Am. J. Gastroenterol. 95 (4), 974-980 (2000).
41. Drossman DA, Patrick DL, Whitehead WE et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am. J. Gastroenterol. 95(4), 999-1007 (2000).
42. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure. Med. Care 190, 787-805 (1981).
43. Bergner M, Bobbitt RA, Pollard WE, Martin DP, Gilson BS. The Sickness Impact Profile: validation of a health status measure. Med. Care 14(1), 57-67 (1976).
44. Pollard WE, Bobbitt RA, Bergner M, Martin DP, Gilson BS. The Sickness Impact Profile: reliability of a health status measure. Med. Care 14(2), 146-155 (1976).
45. Dupuy HJ. The Psychological General Well-being (PGWB) index. In: Assessment of Quality of life in Clinical Trials of Cardiovascular Therapies. Wenger NK, Mattson ME, Furberg CF, Elinson J (Eds). Le Jacq Publishing Inc., CT, US& 170-183 (1984).
46. Dimenäs E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens? Scand. J. Gastroenterol. 28(8), 681-687 (1993).
47. Dimenäs E, Glise H, Hallerbäck B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand. J. Gastroenterol. 30(11), 1046-1052 (1995).
48. Talley NJ, Meineche-Schmidt V, Pare P et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol. Ther. 12(11), 1055-1065 (1998).
49. Havelund T, Lind T, Wiklund I et al. Quality of life in patients with heartburn but without esophagitis: effiects of treatment with omeprazole. Am. J. Gastroenterol. 94(7), 1782-1789 (1999).
50. Simrén M, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern. Scand. J. Gastroenterol. 36(5), 545-552 (2001).
51. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson E. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 97(2), 389-396 (2002).
52. Glia A, Lindberg G. Quality of life in patients with different types of functional constipation. Scand. J. Gastroenterol. 32(11), 1083-1089 (1997).
53. Yacavone RF, Locke GR 3rd, Provenzale DT, Eisen GM. Quality of life measurement in gastroenterology: what is available? Am. J. Gastroenterol, 96(2), 285-297 (2001).
54. Dimenäs E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand. J. Gastroenterol. (Suppl.) 221, 8-13 (1996).
55. Strid H, Simren M, Johansson AC, Svedlund J, Samuelsson O, Björnsson ES. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol. Dial. Transplant. 17(8), 1434-1439 (2002).
56. Fletcher AE, Chester PC, Hawkins CM, Latham AN, Pike LA, Bulpitt CJ. The effects of verapamil and propranolol on quality of life in hypertension. J. Hum. Hyperters. 3(2), 125-130 (1989).
57. Nissinen A, Wiklund I, Lahti T et al. Anti-anginal therapy and quality of life. A comparison of the effects of transdermal nitroglycerin and long-acting oral nitrates. J. Clin. Epidemiol. 44(9), 989-997 (1991).
58. Wiklund I, Karlberg J, Mattsson LA. Quality of life of postmenopausal women on a regimen of transdermal estradiol therapy: a double-blind placebo-controlled study. Am. J. Obstet. Gynecol. 168(3 Pt 1), 824-830 (1993).
59. Irvine EJ. The quality of quality of life. Gut. 44(4), 450-451 (1999).
60. Hahn BA, Kirchdoerfer LJ, Fullerton S, Mayer E. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol. Ther. 11(3), 547-552 (1997).
61. Watson ME, Lacey L, Kong S et al. Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am. J. Gastroenterol. 96(2), 455-459 (2001).
62. Chassany O, Bergmann JF. Quality of life in irritable bowel syndrome, effect of therapy. Eur. J. Surg. Suppl. 583, 81-86 (1998).
63. Chassany O, Marquis P, Scherrer B et al. Validation of a specific quality of life questionnaire for functional digestive disorders. Gut 44(4), 527-533 (1999).
64. Wong E, Guyatt GH, Cook DJ, Griffith LE, Irvine EJ. Development of a questionnaire to measure quality of life in patients with irritable bowel syndrome. Eur. J. Surg. Suppl. 583, 50-56 (1998).
65. Groll D, Vanner SJ, Depew WT et al. The IBS-36: a new quality of life measure for irritable bowel syndrome. Am. J. Gastroenterol. 97(4), 962-971 (2002).
66. Poitras MR, Verrier P, So C, Paquet S, Bouin M, Poitras P. Group counseling psychotherapy for patients with functional gastrointestinal disorders: development of new measures for symptom severity and quality of life. Dig. Dis. Sci. 47(6), 1297-1307 (2002).
67. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol. Ther. 11(2), 395-402 (1997).
68. Svedlund J, Sjödin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 33(2), 129-134 (1988).
69. Drossman DA. Review article: an integrated approach to the irritable bowel syndrome. Aliment Pharmacol. Ther. 13(Suppl. 2), 3-14 (1999).
70. Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of out-patients with irritable bowel syndrome. J. Pychosom. Res. 34(5), 483-491 (1990).
71. Lydiard RB, Fossey MD, Marsh W, Ballenger JC. Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 34(3), 229-234 (1993).
72. Svedlund J, Sjödin I, Dotevall G, Gillberg R. Upper gastrointestinal and mental symptoms in the irritable bowel syndrome. Scand. J. Gastroenterol. 20(5), 595-601 (1985).
73. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch. Gen. Psychiatry 6, 561-571 (1961).
74. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 67(6), 361-370 (1983).
75. Spielberger CD. Manual for the State-Trait Anxiety Inventory (Form Y). Consulting Psychologists Press Inc., CA, USA (1983).
76. Derogatis LR, Rickels K Rock AF. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br. J. Psychiatry 128, 280-289 (1976).
77. Whorwell PJ, McCallum M, Creed FH, Roberts CT. Non-colonic features of irritable bowel syndrome. Gut 27(1), 37-40 (1986).
78. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF. Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin. Infect. Dis. 18(Suppl. 1), S79-83 (1994).
79. Prince MI, James OFW, Holland NP, Jones DEJ. Validation of a fatigue impact score in primary biliary cirrhosis: towards a standard for clinical and trial use. J. Hepatol 32, 368-373 (2000).
80. Payne A, Blanchard EB. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J. Consult. Clin. Psychol. 63(5), 779-786 (1995).
81. Toner BB, Stuckless N, Ali A, Downie F, Emmott S, Akman D. The development of a cognitive scale for functional bowel disorders. Psychosom. Med. 60(4), 492-497 (1998).
82. Toner BB, Segal ZV, Emmott S et al. Cognitive-behavioral group therapy for patients with irritable bowel syndrome. Int. J. Group Psychother. 48(2), 215-243 (1998).
83. Thompson WG, Creed F, Drossman DA, Heaton KW, Mazzaca G. Functional Bowel Disease and Functional Abdominal Pain. Gastroenterol. Inter. 5(2), 75-91 (1992).
84. Irvine EJ, Ferrazzi S, Pare P, Thompson WG, Rance L. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am. J. Gastroenterol. 97(8), 1986-1993 (2002).
85. Frank L, Kleinman L, Rentz A, Ciesla G, Kim JJ, Zacker C. Health-related quality of life associated with irritable bowel syndrome: comparison with other chronic diseases. Clin. Ther. 24(4), 675-89 (2002).
86. Camilleri M, Williams DE. Economic burden of irritable bowel syndrome. Proposed strategies to control expenditures. PharmacoEconomics 17(4), 331-338 (2000).
87. van der Horst HE, van Dulmen AM, Schellevis FG, van Eijk JT, Fennis JF, Bleijenberg G. Do patients with irritable bowel syndrome in primary care really differ from out-patients with irritable bowel syndrome? Gut 41(5), 669-674 (1997).
88. Drossman DA, McKee DC, Sandler RS et al. Psychosocial factors in the irritable bowel syndrome. A multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 95(3), 701-708 (1988).
89. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br. Med. J. 2(6138), 653-654 (1978).
90. Mearin F, Badia X, Balboa A et al. Irritable bowel syndrome prevalence varies enormously depending on the employed diagnostic criteria: comparison of Rome II versus previous criteria in a general population. Scand. J. Gastroenterol. 36(11), 1155-1161 (2001).
91. Saito YA, Locke GR, Talley NJ, Zinsmeister AR, Fett SL, Melton LJ 3rd. A comparison of the Rome and Manning criteria for case identification in epidemiological investigations of irritable bowel syndrome. Am. J. Gastroenterol. 95(10), 2816-2824 (2000).
92. Badia X, Mearin F, Balboa A et al. Burden of illness in irritable bowel syndrome comparing Rome I and Rome II criteria. PharmacoEconomics 20(11), 749-758 (2002).
93. Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N. Patient-reported outcomes: The example of health-related quality of life -a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inform. J. 36, 209-238 (2002).
94. Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res. 9(8), 887-900 (2000).
95. Santanello NC, Baker D, Cappelleri JC et al. Regulatory issues for health-related quality of life - PhRMA Health Outcomes Committee workshop, 1999. Value Health 5(1), 14-25 (2002).
96. Mathias JR. Clench MH, Abell TL et al. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease: a double-blind, placebo-controlled, randomized study. Dig. Dis. Sci. 43(6), 1347-1355 (1998).
97. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 355(9209), 1035-1040 (2000).
98. Thompson CA. Alosetron withdrawn from market. Am. J. Health Syst. Pharm. 58(1), 13 (2001).
99. Watson ME. Minimum meaningful difference scores for the irritable bowel syndrome quality of life questionnaire (IBSQOL). Value Health 3, 54-55 (2000).
100. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig. Dis. Sci. 40(10), 2244-2249 (1995).
101. Gonsalkorale WM, Houghton LA, Whorwell PJ. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am. J. Gastroenterol. 97(4), 954-961 (2002).
102. Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome-the effect of hypnotherapy. Aliment Pharmacol. Ther. 10(1), 91-95 (1996).
103. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1(3), 277-299 (1975).